CARLSBAD, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the limited commercial launch of its Regatta Lateral Plate System. Marking the first standalone lateral plate for SeaSpine, this Lateral Lumbar Interbody Fusion (LLIF) fixation system allows for multiple plating options, including one, two, and four-hole plates. The addition of SeaSpine’s TruProfile® technology is designed to bring maximum fixation with minimum profile and address a wide range of anatomy and pathologies, while minimizing the need for additional retractor expansion.
“The Regatta Lateral Plate provides me with the options, confidence, and ease of use that has been missing from the market,” said Dr. Kevin O’Neill with OrthoIndy in Indianapolis, IN. “The ability for the plate to seamlessly attach to the Regatta Interbody allows for a lower profile plate that reduces the need for me to further open my retractor and eliminates bulky instrumentation.”
The Regatta Lateral Plate is designed to easily integrate with the Regatta Interbody to provide the best plate option for minimal psoas disruption and vertebral body overhang. Two different locking mechanisms allow for both separate standalone LLIF fixation for the two and four-hole plates and a robust temporary fixation for the one-hole plate.
“This next generation lateral fixation solution adds value and versatility to our expanding Regatta lateral product portfolio and represents our drive to meet the needs of the surgeon for better patient outcomes in lateral surgeries,” said Dennis L. Cirino, Senior Vice President, Global Spinal Systems. “Combined with our NanoMetalene® implant portfolio, proprietary and market leading Osteostrand® Plus DBM fibers and our existing Regatta access instrumentation, SeaSpine continues to provide complete procedural solutions for surgeons to address the least to most complex surgical challenges.”
About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.
Forward-Looking Statements
SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to: the objectives of product design and the ability of the underlying products to achieve design objectives, including bringing maximum fixation with minimum profile, addressing a wide range of anatomy and pathologies, minimizing the need for additional retractor expansion, and the ability for the plate to attach or integrate to the Regatta Interbody, thereby minimizing psoas disruption, vertebral body overhang and bulky instrumentation; and the ability for SeaSpine to continue to provide complete procedural solutions for surgeons to address the least to most complex surgical challenges. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the ability of newly launched products to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of clinical validation of products in limited commercial (or “alpha”) launch; unexpected delay, including as a result of developing and supporting the launch of new products, including as a result of obtaining regulatory clearances; and other risks and uncertainties more fully described in the Company’s news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.
Investor Relations Contact
Leigh Salvo
(415) 937-5402
ir@seaspine.com
